Drug DevelopmentThe company has expanded its drug discovery capabilities with exclusive access to the HUNT Biobank in Norway.
Financial StabilityBioAge Labs has a strong cash position, with $313.4M in cash and equivalents, expected to support operations through 2029.
Strategic PartnershipsDiscovery collaborations with major companies like Novartis and Lilly are progressing, focusing on novel targets related to aging and exercise.